Soleno Therapeutics is proud to announce a monumental funding milestone, having raised $200,000,000 to further our mission of transforming lives within the rare disease community. Our commitment to harnessing the power of science, advocacy, and community has been unwavering since our inception, and this latest infusion of capital not only reaffirms our vision but also accelerates our journey toward innovative healthcare breakthroughs. As many in the Prader-Willi syndrome (PWS) community know, our pioneering work led to the FDA approval in March 2025 of the first and only therapy for the treatment of hyperphagia associated with PWS. This groundbreaking treatment stands as a beacon of hope and a testament to our expertise and relentless pursuit of excellence in addressing the challenges posed by rare diseases.
The new funding will be strategically allocated to expand our research and development initiatives, bolster clinical trials, and enhance our global outreach programs to better serve our community. By deepening our scientific exploration and forging stronger advocacy partnerships, we aim to unlock further advancements that could radically improve the quality of life for individuals impacted by rare diseases. We also plan to invest in state-of-the-art technologies and infrastructure that will drive future discoveries and support our commitment to ensuring that no voice within our community is left unheard. At Soleno Therapeutics, we remain honored to work side by side with patients, families, and healthcare professionals to push the boundaries of what is possible. For more information on our journey and ongoing projects, please visit soleno.life.
